Insulin glargine combined with metformin — Competitive Intelligence Brief

Insulin glargine combined with metformin (Insulin glargine combined with metformin) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin + biguanide combination. Area: Diabetes.

marketed Insulin + biguanide combination Insulin receptor (insulin glargine); AMP-activated protein kinase and mitochondrial complex I (metformin) Diabetes Small molecule

Target snapshot

Insulin glargine combined with metformin (Insulin glargine combined with metformin) — Sun Yat-sen University. This combination uses insulin glargine to provide basal insulin replacement while metformin reduces hepatic glucose production and improves insulin sensitivity.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin glargine combined with metformin TARGET	Insulin glargine combined with metformin	Sun Yat-sen University	marketed	Insulin + biguanide combination	Insulin receptor (insulin glargine); AMP-activated protein kinase and mitochondrial complex I (metformin)
CSII followed by MET	CSII followed by MET	Sun Yat-sen University	marketed	Insulin + Biguanide combination regimen	Insulin receptor (insulin); AMP-activated protein kinase pathway (metformin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin + biguanide combination class)

1. Sun Yat-sen University · 1 drug in this class